A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis

NCT06506916 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate to Severe Plaque Psoriasis
Psoriatic Arthritis

Interventions

DRUG: bimekizumab

Sponsor

UCB Biopharma SRL